DURHAM, NC - September 8, 2009 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas R. Staab, II, Chief Financial Officer and Treasurer, will present at the Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 15, 2009 at 8:00 am ET, Christy L. Shaffer, Ph.D., President and CEO, will present at the BioCentury Newsmakers Conference on Wednesday, September 16, 2009 at 3:00 pm ET and Benjamin R. Yerxa, Ph.D., Executive Vice President and Chief, Research and Development, will present at the UBS Global Healthcare Conference on Tuesday, September 22, 2009 at 9:00 am ET. These presentations will take place in New York City.
The webcasts of the presentations will be available on Inspire’s web site at www.inspirepharm.com. An archived version of the webcast presentations will also be available through this link for a limited time following the conference.
About Inspire
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire’s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical and scientific expertise. The most advanced compounds in Inspire’s clinical pipeline are Prolacria(TM) for dry eye and denufosol tetrasodium for cystic fibrosis, which are both in Phase 3 development and AzaSite(R) for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AzaSite for bacterial conjunctivitis, the co- promotion of Elestat(R) for allergic conjunctivitis and royalties based on net sales of Restasis(R) for dry eye. For more information, visit www.inspirepharm.com.
